Vaccine scandal. After the scandal in March, the Chinese Ministry of Health is expected to increase strict monitoring of the manufacturing and supply chain
for vaccination products. In the long run, bigger-scale manufacturers may take market share away from smaller brands, and foreign companies will benefit.
Overseas acquisition of Foreign Hospitals. As capital and funds are investing on domestic private sectors, Chinese investors also are looking at overseas
assets to allow rapid catch-up with the best practices of international operations.
l Class I vaccine would expand. OCR’s Monthly Interview: affordability and reimbursement is key for the market expansion of the Vaccine Industry.
Companies to watch. GlaxosmithKline and Sanofi are likely to be major beneficiaries of the vaccine scandal.